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Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic
resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This
publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies,
recommending how this new tool might best be used.
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Recent developments in our understanding of the cancer genome,
and the control of molecular processes important to the
development and regulation of cancer cells, are leading to the
identification of many new targets for cancer therapeutics (Kohn
et al, 2004). This increased understanding has been accompanied
by new technologies that speed up the search for, and development
of, new therapeutics (Workman and Kaye, 2002). Given the greater
specificity of new agents against target processes, together with
an expected growth in the number of such agents being proposed
for clinical trial, the New Agents Committee (NAC) of Cancer
Research UK, which approves and supports clinical trials of
promising cancer therapeutics, is placing considerable emphasis
on incorporating end points that provide evidence that the desired
activity has been achieved into new trials (Newell et al, 2003). To
assist in this, the Pharmacodynamic/Pharmacokinetic Techno-
logies Advisory Committee (PTAC) reviews submissions to the
NAC for new therapeutics being considered for further develop-
ment or clinical trial, to identify and advise on the incorporation of
pharmacodynamic and pharmacokinetic assessment into early-
stage clinical trials (http://science.cancerresearchuk.org/tcr/drug-
development/newagentscomm/ptac). Where possible, PTAC is
looking for trial designs that test whether the therapy is working
by its intended process (Workman, 2002, 2003). Guidelines and
advice are available at http://science.cancerresearchuk.org/reps/
pdfs/PTACguidelines.pdf. While morphological tumour size
change remains an important measure of response, in early-stage
trials, or in the evaluation of cytostatic or antiproliferative agents,
volume change may not be a sensitive-enough measure of the
biological activity of an agent. In the setting of early-stage trials
performed on patients with advanced and refractory disease,
treatments may affect a proportion of cells but not translate into
volume reduction. Therapeutics targeted at tumour vasculature or
its control provide an example of a class of treatments where
functional imaging may provide earlier or more specific informa-
tion than morphological imaging.
Tumour vasculature presents an important target for therapeu-
tic development, with agents acting on the vascular endothelium
(antivascular therapies) (Thorpe, 2004) or the process of
neoangiogenesis (antiangiogenic therapies) (Bicknell and Harris,
1996). Magnetic resonance imaging (MRI) has shown promise as a
method of evaluating tumour vasculature, potentially monitoring
the effect of these therapies (Taylor et al, 1999; George et al, 2001;
Padhani and Husband, 2001; Padhani et al, 2001; Galbraith et al,
2002, 2003; Morgan et al, 2003; Neeman and Dafni, 2003). The
PTAC has recently considered a number of applications to evaluate
these classes of therapeutic agent, with proposals to employ MRI
to assess activity. In considering these proposals, it was clear that
investigators would be helped by guidelines defining requirements
for MRI investigations in early-stage trials of antivascular and
antiangiogenic therapies. To this end, PTAC convened a workshopReceived 7 March 2005; accepted 7 March 2005
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to address these issues, and to provide appropriate guidelines. The
workshop considered the types of therapeutic and their effects;
the requirements of clinicians and industry; the potential MRI
approaches, what they measured and the reproducibility of the
techniques; the approaches taken in alternative methods of
vascular evaluation. Several different panels, detailed in the
Appendix, comprised of the authors of this report, then considered
the various specific and important issues involved in applying MRI
to antivascular and antiangiogenic therapies, and developed
guidelines for such use. This report summarises the presentations
and conclusions of the panels, together with the recommended
guidelines.
THERAPEUTIC DEVELOPMENT, ANTIVASCULAR
AND ANTIANGIOGENIC THERAPIES (BOXES 1 AND 2)
In building on the increasing pace of target discovery and the
development of potential therapeutics, there is a need to evaluate
the effects of drugs on their biological targets in vivo, and to
perform clinical trials more effectively. Some of the important
questions are listed in Box 1.
Pharmacokinetic assays such as liquid chromatography –mass
spectrometry (LC–MS) can define plasma concentrations of
agents. However, some of the powerful pharmacodynamic assays
that assess biological effect, such as array technology or
immunohistochemical methods, require tissue and are surgically
invasive. This raises ethical and logistical difficulties in incorpo-
rating these assays into clinical trials. This is particularly the case
where the timing of peak biological effect post-treatment is not
known. Noninvasive imaging methods are more acceptable, are
generally not limited to biopsy-accessible sites and may permit
more frequent measurements.
There is a wide range of compounds that affect vascular function
(Li, 2000). Their effects are summarised in Box 2. Antiangiogenic
agents (Verheul and Pinedo, 2003; Alessi et al, 2004; Cao, 2004)
include inhibitors of vascular endothelial growth factor (VEGF),
receptor tyrosine kinase inhibitors, inhibitors of other receptors
and signalling pathways (e.g. FLT1, PI3 kinase, HIF) and
angiostatin-like agents. These agents are directed at inhibiting or
disrupting the growth of tumour neovasculature. In addition, a
wide range of other agents, including inhibitors of matrix
metalloproteinases, anti-cytokines and general cytotoxics, may
have vascular-directed effects. Examples of antiangiogenic agents
include vatalanib, bevacizumab, ZD6474, SU11248, AGM-1470 and
PTK787/ZK222584. Antivascular agents (Siemann et al, 2004;
Thorpe, 2004) include Combretastatin A4 phosphate, ZD6126 and
5,6-dimethylxanthenone-4-acetic acid (DMXAA). These are direc-
ted against the vascular endothelium, resulting in collapse of
tumour vasculature.
WHAT CAN MRI MEASURE?
Magnetic resonance imaging methods provide an attractive means
of investigating vascular end points since they are widely available,
noninvasive and involve no ionising radiation. At the simplest
level, MRI gives anatomical information, with the powerful
potential to manipulate the relative contrast of different tissues.
In practice, the MRI method that is almost invariably used for
vascular studies is dynamic contrast-enhanced MRI (DCE-MRI).
This involves injection of a contrast agent and acquisition of a
series of images; the curve of signal intensity change indicates the
rate of uptake of the contrast agent into the tumour and its
subsequent washout. Dynamic contrast-enhanced MRI is widely
used in radiological practice for diagnostic purposes, and in this
role interpretation usually involves subjective judgements about
the shape of the uptake curve and the morphology of enhancing
tissues. In drug trials, quantifiable parameters aid assessment of
change and of dose-related effects. A range of techniques to make
quantitative measurements have been reported (Collins and
Padhani, 2004), allowing parameters descriptive of vascular
physiology and processes to be calculated. However, the physio-
logical significance of these parameters can be complex, and there
is currently no consensus as to the best parameters to be used, or
the most appropriate measurement and analysis methodology.
Magnetic resonance imaging predominantly images water
molecules in the body. By exploiting specific properties of
magnetic resonance and of water, a number of approaches to
assessing tissue vasculature and vascular properties have been
developed. These provide methods of assessing antiangiogenic and
antivascular therapies. In an MRI investigation, these functional
measurements can be combined and registered with high-quality
morphological images, allowing conventional size assessment,
identification of heterogeneity and visualisation of adjacent
structures.
Magnetic resonance methods of assessing vasculature and
vascular properties can be divided into:
Box 1 Issues relating to therapeutic development
Important to know if the drug is:
K Reaching required concentration in the effecting compartment.
K Affecting desired molecular target.
K Modulating the biochemical pathway.
K Achieving desired biological effect on the tumour cell.
K Achieving desired physiological effect on the tumour.
There is a requirement for noninvasive assays, particularly when timing of peak
biological activity is not known.
Aim for hypothesis testing trials to:
K Support go/no go decisions: accelerate drug development or kill failures
early.
K Establish dose and time response (scheduling).
K Examine drug combinations.
K Provide confidence to go forward to expensive large-scale trials.
In this context, MR measurements are biomarkers, where, following the NIH
Biomarkers Definitions Working Group (2001), a biomarker is a ‘characteristic
that is objectively measured and evaluated as an indicator of normal biological
processes, pathogenic processes or pharmacologic responses to a therapeutic
intervention’ as distinct from a surrogate end point, which, when validated, is
expected definitively to predict clinical benefit. Surrogate end points generally
require evidence of validation for regulatory bodies.
Aim to operate the analysis at a level of computer software validation between
publication standard quality assurance and ICH GCP (1996).
Have realistic guidelines (resource issues – who pays to develop methods and
maintain facilities?).
Box 2 Effects of antiangiogenic and antivascular therapeutics
Antiangiogenic therapy
K Inhibition of growth factor support of neovasculature.
K Reduced permeability.
K Reduced perfusion.
K Reduced blood volume.
Antivascular therapy
K Collapse of proliferating vasculature.
K Possible collapse of mature tumour vasculature.
K Loss of permeable vasculature.
K Reduced perfusion/flow.
K Reduced blood volume.
K Reduced tortuosity.
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(1) visualisation and assessment of vascular structures including
MR angiography,
(2) assessment of vascular delivery of molecules to the extra-
vascular space,
(3) measurement of blood volume and
(4) measurement of perfusion.
Magnetic resonance contrast agents utilise atoms or compounds
with magnetic properties that will affect hydrogen atoms in water
molecules, changing the signals measured. The most common
agents utilise chelates containing paramagnetic atoms such as
gadolinium (Gd), which have one or more unpaired electrons,
resulting in a strong electronic magnetic moment. This local
magnetic field can alter (relax) the magnetic state of the hydrogen
atoms in water, changing their T1 relaxation time (an MR
parameter describing their response to MR measurements) causing
an increase in signal on T1-weighted MR images. Strong
concentrations of Gd-containing contrast agents can also change
the local magnetic field (changing magnetic susceptibility). This
causes a local loss of signal due to dephasing, which is described by
T2* relaxation, and can be seen as a loss of signal on T2*-weighted
sequences. The paramagnetic atom is chelated in a compound that
will define the pharmacokinetic behaviour of the compound in the
body. Most agents currently in clinical use are low-molecular-
weight compounds (MWo1000), without specific targeting
properties, but which can diffuse through normal endothelial
junctions (Schneider and Uder, 2003). However, more complex
high-molecular-weight agents are being developed, some of which
may act as blood pool agents, and others may be substrates for
specific processes (Brasch and Turetschek, 2000; Turetschek et al,
2004). A particularly important feature of all these approaches is
that the contrast agent is not being measured directly, rather it is
the effect that it has on the very many water atoms that can visit
the Gd that is measured, effectively amplifying the effect of each
molecule of contrast agent.
Conventional MR imaging compares similar images with and
without the contrast agent. Thus compared with precontrast
images, T1-weighted images after contrast will show bright areas
where the Gd-containing contrast agent has been delivered to the
extracellular space. This approach is routinely used in MRI,
particularly in the brain where uptake of Gd shows breakdown of
the blood–brain barrier. Usually, such images are taken at a few
minutes after contrast administration, but in some tissues, it is
important to make measurements at shorter time periods, as the
contrast agent can washout rapidly. More recently, there has been
interest in following the dynamic uptake of the contrast, and a set
of rapid images have been used, allowing the time course of
intensity changes to be measured in a region of interest (ROI). This
can provide diagnostic information, for example in the diagnosis
of breast cancer (Leach, 2001). To cause enhancement, the agent
must be delivered to the tumour, and must leak into the
extracellular space, providing information on perfusion, on
endothelial permeability and on the volume of the extracellular,
extravascular space. This approach is particularly sensitive to
developing neovasculature in tumours, which is dependent on
VEGF and other growth factors generated by primary and
metastatic tumours (Choyke et al, 2002; Strecker et al, 2003).
Analysis of the dynamic image series can be used to calculate
parametric maps of pharmacokinetic parameters, or of parameters
based on physiological models, with a spatial resolution of
typically 1 –2 mm (see Figure 1). Definitions and terms used in
parametric measurements are defined in Box 6.
When a bolus of contrast agent passes through the vasculature,
having a high concentration of contrast, it changes the magnetic
susceptibility of the blood, causing large magnetic field gradients
compared with surrounding tissues. This results in local signal loss
on T2*-weighted images, which can provide information on
vascular concentrations of agent, but can also generate informa-
tion on vessel dimensions, as the size and extent of the effect is
dependent on vessel diameter. Sequences that have a different
sensitivity to vascular dimensions (such as spin-echo or gradient-
echo sequences) can also be used to probe vascular size. In
addition, blood provides an intrinsic contrast, with the degree of
oxygenation affecting signal intensity on T2-weighted sequences.
Oxyhaemoglobin is diamagnetic, whereas deoxyhaemoglobin is
paramagnetic. Thus, deoxygenated blood causes more signal loss
on T2*-weighted images, a phenomenon exploited in blood oxygen
level-dependent (BOLD) imaging (Howe et al, 2001) and brain
activation studies (Hennig et al, 2003). This approach can be
further exploited by using vasomodulators such as carbogen,
which will preferentially affect physiologically responsive mature
vasculature. These techniques probe vascular structure at a
resolution below that of the imaging method. Many trials of new
antiangiogenic or antivascular agents already include DCE-MRI
measurements to provide biomarkers of therapeutic action
(Galbraith et al, 2002, 2003; Jayson et al, 2002; Morgan et al,
2003; Yang et al, 2003). In principle, some of the other methods
described above can be included in such studies to increase the
information obtained.
CLINICAL VIEW (Box 3)
Increasingly, early-stage clinical trials are being designed to
provide information on biomarkers of therapeutic effect, in
addition to establishing pharmacokinetics, safety and tolerability
for single agents and combinations. Evidence from these trials that
agents are acting on their intended target increases confidence in
the value of taking them through to larger stage trials of efficacy, or
can inform further development. Some issues relating to clinical
Figure 1 Example of Ktrans maps, superimposed on T1-weighted images
of a patient with primary peritoneal carcinoma with left pelvic side wall
nodal metastases (arrow). Images are before and 4 h after the first dose of
Combretastatin (52 mg m2). The colour scale ranges from Ktrans values of
0 to 1 min1. A dramatic reduction of transfer constant is seen. This was
published with kind permission from the Journal of Magnetic Resonance
Imaging (Padhani, 2002).
Box 3 Clinical issues
K Antiangiogenic therapies may have most effect on small tumours – not
those traditionally monitored in phase I/II trials – challenging for MRI.
K In the absence of volume response, functional measurement information
or biopsy may be required to gain the confidence to go to major phase III
trials evaluating efficacy.
K What is the correct timing for measurements?
K To what extent can information from preclinical models guide clinical
measurements?
K Can a dose-response be identified?
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application of MR techniques are summarised in Box 3.
Techniques used in hypothesis testing trials need to be robust,
practicable in a clinical setting and acceptable in terms of
invasiveness. Approaches need to be properly evaluated and be
compatible with ICH Good Clinical Practice (ICH, 1996).
Antiangiogenic agents are expected to be most effective on
immature new vasculature, with small emerging tumours most
likely to exhibit neoangiogenesis and so respond to such
treatment. Thus, the maximum benefit might be seen in an
adjuvant setting. Imaging techniques are, however, best suited for
evaluating larger tumours that can be clearly resolved and
separated from other tissue structures. Patients chosen for early-
stage clinical trials often have received multiple treatments or have
stable metastatic disease, resulting in a mature vascular phenotype.
Early-stage clinical trials on advanced disease therefore may not
provide evidence of volume response, but changes in vascular
function in defined areas of tumour may support the hypothesis
under test. Robust statistical techniques may be needed to identify
these effects. Sufficiently sensitive techniques may indicate
whether the agent has an impact on a proportion of the tumour
vasculature. Some metastases may provide imaging targets with a
high proportion of neovasculature. It will be important to separate
direct vascular effects of treatment from vascular change resulting
from cytotoxic action on tumour cells. Later stage trials may,
however, require evidence of an improvement in progression-free
survival rather than of an arrest of progression.
Antivascular agents, such as cytoskeleton-interacting drugs,
cause acute vascular collapse. These effects seem to be rapidly
reversible, but may have less effect on more mature vessels. They
may be most effective as combination therapy with cytotoxics or
antiangiogenics. To move these agents through to clinical use, it
is necessary to establish that they cause clinically useful disease
stabilisation. As bulk tumour response may be hard to obtain in
advanced disease, surrogates such as biopsy studies or imaging
may be required to define an effective dose and provide sufficient
confidence to progress to phase III trials.
PHARMACEUTICAL INDUSTRY VIEW (Box 4)
The requirement for identifying imaging end points for therapeutic
evaluation comes from the imperatives of portfolio management.
There are many potential targets to choose from, and multiple
possible molecules to affect each target. These cannot all be taken
through to stage III therapeutic trial. Thus, it is necessary for the
pharmaceutical industry to rationalise the development process to
minimise the costs of developing new agents, while at the same
time accelerating drug development and minimising patient
exposure to ineffective drugs/doses. In this context, the main
interest in functional imaging end points are in phase I/IIa trials
with the objectives of obtaining an acute marker of biological
efficacy (ideally pharmacodynamic), identifying the biologically
effective dose, which may be much less than the maximum
tolerated dose (MTD), and evaluating scheduling options and
possible combination therapies. In this context, it is important to
note that MR-measurable effects, which report on aspects of
overall vascular function (see section What can MRI Measure),
may not strictly reflect the concentration of the drug (due to the
complexity of vascular function and control, and the time course
of treatment effects). Major issues are summarised in Box 4.
Industry places considerable emphasis on studies delivering
appropriate data. The imaging study must be feasible. Repeat scans
should be practicable and acceptable to patients. The method
should be implementable in a multicentre study. It should be
feasible in all the chosen and relevant anatomical locations
especially in the advanced disease typically encountered in phase
I/II trials. Analysis should be robust and reliable. The approach
should be thoroughly evaluated and be widely accepted. There
should be a well-understood link to the underlying molecular
pharmacology in order to distinguish alternative mechanisms. It
should be likely to predict clinical response, but may not
necessarily be accepted by regulatory bodies such as the US Food
and Drug Administration (FDA) as a valid surrogate end point.
The measurement method should be sufficiently well understood
for a clear primary end point to be established prospectively. It
should provide good and known statistical power throughout the
dose–response curve, with potential confounds being understood
and controlled. While it was thought desirable that the measure-
ment and analysis process should meet the requirements of ICH
Good Clinical Practice (GCP) (ICH, 1996), there is recognition that
the investment of resources required for the validation of
computer software, which is extremely onerous, might be
unrealistic, and could inhibit the imaginative use of novel
techniques. The other extreme would be to work to ‘publication
standard’, using investigator written software. However, this
requires maintenance of expertise in the software, implying long-
term investment by the investigator’s institution in this capability.
Ideally, some robust medium position between ICH GCP and
‘publication standard’ is required for the analysis, together with
mechanisms for funding, maintaining and sharing the necessary
measurement, evaluation and quality assurance methods and
resources.
Prior to a clinical trial, the practicalities need to be addressed.
The methodology should be developed, established and validated
beforehand, and animal studies to inform study design should
have been performed. The method of identifying and delineating
the lesion needs to be defined, including who will draw the ROI or
volume of interest (VOI), and how many lesions will be measured.
The type of analysis must also be specified, clearly indicating the
methods used. Standard radiologist’s imaging reports can readily
identify powerful drug effects but cannot provide a basis for
establishing a dose–response relationship; nonpharmacokinetic
quantification such as numerical descriptors of uptake-curve
shape (e.g. maximum intensity time ratio (MITR); some examples
are given in Brown et al, 2000) is based on signal intensity changes
and may not translate between centres. Parameters may be
determined from standard pharmacokinetic models (Ktransy);
from more advanced pharmacokinetic models, including vascular
input functions; or from integration of the contrast agent
concentration curve (IAUGC). Standard terms are defined in Box
5. The quantification needs to be fit for purpose, and should
include the generation of information that is necessary to robust
characterisation and intercentre consistency, such as the input
function or the native T1 relaxation time. Issues relating to
heterogeneity need to be addressed, such as whether single-slice
or three-dimensional (3D) analyses are required, whether model
Box 4 Pharmaceutical industry view
K MR end points may aid selection of leads from many targets and
therapeutic agents, for eventual phase III trials, reducing lead-time and
costs.
K Ideally identifies markers of biological efficacy, guiding effective dose,
scheduling and combinations.
K MR effect may not give a dose-response.
K Alternative methods of interest include PET, infrared, CT, U/S.
K Studies should be feasible, analysis should be robust.
K Approach should have widely accepted validity.
K Method should enable standardised implementation across several
centres.
K A clear primary MR end point should be established prospectively.
K Type of analysis should be specified prospectively.
K There is a tension between industry preference for ICH GCP, academic
preference for publication standard, the imperatives driving academic and
clinical centres and the availability of funding to establish methodology to
achieve these standards.
Antiangiogenic and antivascular therapies and MRI
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fitting should be performed on ROI data or pixelwise. If pixel-by-
pixel analysis is performed, should such analysis use the median,
or should more complex analysis based on the histogram of values
within the lesion be employed? This should be established and
documented prospectively.
The limitations of animal models in defining the size of effects to
be expected, as well as their timing, were considered. Such
measurements were viewed as important in functional imaging
studies, both to give guidance on the timing and maximum effect,
and also to aid in the interpretation of clinical results. Data should
be capable of independent review, but should not be expected to
reach a standard that could not be attained at most centres, as this
could adversely affect the introduction of these new approaches.
There is concern as to who would pay for the validation of these
new methods, as there is a tension between the requirements of
academic research funders who fund new science and the
requirements of individual pharmaceutical companies who wish
to support development of their own agents, desiring computer
system validation in compliance with ICH GCP standards to
support decisions that have major financial implications.
RECOMMENDATIONS FOR MR MEASUREMENT AND
ANALYSIS METHODS, END POINTS AND
NOMENCLATURE FOR USE IN PHASE I/IIA TRIALS
OF ANTICANCER THERAPEUTICS (BOXES 5 AND 6)
Measurement methods
When MRI is used for the pharmacodynamic assessment of
antivascular and antiangiogenic agents, it is recommended that
DCE-MRI should be performed with low-molecular-weight Gd
chelates, because of the well-established sensitivity of this
approach to perfusion and endothelial permeability. Noncontrast
MRI measurements may be included in addition to DCE-MRI.
Magnetic resonance imaging measurements with high-molecular-
weight contrast agents are expected to add a great deal to the
quantitation and specificity of these measurements, but high-
molecular-weight agents are not yet generally available for use in
phase I/IIa trials of anticancer therapeutics. Dynamic contrast-
enhanced MRI is widely used in radiology. If a compartmental
model is assumed, kinetic parameters from DCE-MRI studies can
be assessed by quantifying contrast agent concentration change or
DR1 (i.e. the change in 1/T1) and then using pharmacokinetic
modelling techniques. An alternative quantitative approach, which
does not assume any particular model, is the initial area under the
Gd concentration–time curve, IAUGC. Some investigators how-
ever have relied on the semiquantitative analysis of signal intensity
changes. Semiquantitative parameters have the advantage of being
relatively straightforward to calculate, but have significant
limitations. These limitations include the fact that semiquantitative
parameters may not accurately reflect contrast agent concentration
in the tissue of interest and can be influenced by the contrast agent
injection procedure and the scanner settings (including the pulse
sequence, gain and scaling factors) and target position in the
image. These factors limit the usefulness of semiquantitative
parameters because between-patient and between-system compa-
risons are difficult. It is also unclear what these parameters reflect
physiologically and how robust they are to variations of cardiac
output. As such, semiquantitative parameters are not recom-
mended for the evaluation of antiangiogenic/antivascular clinical
trials. In general, quantitative measurement techniques are used
when modelling tissue contrast agent concentration although some
workers model signal intensity, making the assumption that signal
intensity changes are proportion to contrast agent concentration
changes (Brix et al, 1991; Buckley et al, 1994; Hoffmann et al,
1995). Quantitative T1 changes measured during a dynamic
enhancement acquisition can be used to estimate contrast agent
concentration in vivo (Brookes et al, 1996; Parker et al, 1997,
2000). Concentration– time curves are then mathematically fitted
using one of a number of recognised pharmacokinetic models
(Tofts et al, 1999) and quantitative modelling parameters are
derived. Standardised terms should be used as defined by Tofts
et al (1999) (see Box 5).
Magnetic resonance measurements to address the primary end
points need methods capable of rapidly measuring contrast agent
concentration, by assessing tumour T1 relaxation times. This
requires an estimate of the effective relaxivity of the chosen
contrast agent in tumour vasculature and tissue. This relaxivity
may be different from the relaxivity in pure water, because of water
exchange and protein binding. To calculate contrast agent
concentration, measurements also need to assess the native T1 of
the tissue. This requires the use of quantitative imaging
techniques, which need to be validated against test objects. Many
methods are available for the assessment of T1, but the faster
methods (progressive nutation) are vulnerable to error due to
radio frequency field inhomogeneity and mis-set pulses (Gowland
and Stevenson, 2003; Parker and Padhani, 2003). The accuracy of
T1 measurements should be verified for every spatial location, coil
Box 5 Nomenclature and methods of analysis
Nomenclature
K Standardised terms should be employed as defined by Tofts et al (1999).
Primary end points
K Ktrans or transfer constant reflects contrast delivery (perfusion) and
transport across the vascular endothelium (permeability), with the
dominant factor depending on whether delivery is flow or permeability
limited. Values are derived by converting DCE-MRI data to contrast
concentration, to which a pharmacokinetic model is fitted.
K IAUGC (initial area under the Gd concentration time curve) does not
require a model, but does not have a simple relationship to physiology. It
is a relatively robust and simple technique, although requiring quantitative
T1 measurements.
Secondary end points based on quantitative techniques
K vb (blood volume) can be derived from T2* first-pass studies or from T1-
weighted modelling techniques.
K kep is a function of K
trans and ve, describing contrast agent efflux from
tumour.
K ve (extravascular extracellular space (EES)) may reflect cellular density.
K Macromolecular contrast agents, although not yet recommended for
trials of new therapeutic agents, are of value for preclinical experimental
work. They can measure
K PS (endothelial permeability) and vp (fractional plasma volume)
without flow contamination.
K Measurements of PS may be hindered by low vascular leak into
tumours, requiring long measurement times and showing poor signal
to noise (particularly for T1-weighted measurements).
Analysis
K Model analysis should be based on the well-accepted Tofts or equivalent
models, but with inclusion of arterial input normalisation, blood volume
and classification of fit failures.
K Estimates of uncertainty should monitor model fitting and w2 error,
mapping this factor and including it in error analysis.
K Fit failures should be categorised as model fit failure (possibly multiple
classes), no enhancement or noise.
Data analysis
K ROI or VOI analysis, based on whole tumour mean values, may not
evaluate tumour heterogeneity, although it may be robust to motion. It
may not reflect small areas of rapid change and so may be insensitive.
K Pixel mapping allows all data to be evaluated, allowing description and
evaluation of regional change. Individual pixels will have relatively poor
signal to noise.
K Analysis techniques, such as histogram and principal components analysis,
may yield sensitive assessment of change.
K ROI placement needs to be supported by method of definition, and
recorded to permit re-evaluation.
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and MR scanner deployed in the study. This implies incorporation
of an appropriate quality assurance programme, which is
particularly important for multicentre trials.
Recommendations for the associated nomenclature and analysis
approaches are provided in Box 5. Recommendations for
measurement methods and end points are summarised in Box 6.
Primary end points
It is recommended that the primary end points in phase 1/2a MRI
trials of oncology therapeutics should be either Ktrans (min1) or
IAUGC (mM Gd min).
Ktrans or transfer constant is the most widely accepted kinetic
parameter, describing the transendothelial transport of low-
molecular-weight contrast medium into the extravascular –extra-
cellular space by diffusion (Tofts et al, 1999). The interpretation
of Ktrans is dependent on the tissue being evaluated and on the
underlying physiological circumstances. If the delivery of the
contrast agent to a tissue is insufficient (flow-limited situations or
where vascular permeability is greater than inflow), then blood
perfusion will be the dominant factor determining contrast agent
kinetics and Ktrans approximates to tissue perfusion per unit
volume (Taylor et al, 1999; Tofts et al, 1999). If tissue perfusion is
sufficient and transport out of the vasculature does not deplete the
intravascular contrast agent concentration (non-flow-limited
situations, i.e. permeability-limited), then transport across the
vessel wall is the major factor that determines contrast agent
kinetics. In tumours, the truth is likely be somewhere between the
two. We can say that the transfer constant is approximately equal
to the smaller of the permeability surface area product (PS) or
perfusion (F), that is, KtransEmin(PS,F). Ktrans is obtained from
simple compartmental models (Tofts et al, 1999). Although Ktrans
is a complex function of tumour blood flow, endothelial surface
and endothelial permeability (Tofts et al, 1999), an effective agent
will be expected to reduce some or all of these fundamental
physiological parameters and it should therefore decrease Ktrans.
IAUGC is a phenomenological description of the early part of
the Gd uptake curve (Evelhoch, 1999). IAUGC does not require any
curve-fitting, or knowledge of an accurate physiological model,
and so is expected to be more robust than Ktrans, which can be
vulnerable to fit failures in the case of highly vascular regions, very
poorly perfused regions or physiological motion. It is calculated
from the area under the contrast agent concentration curve up to a
specified cutoff time (usually 60 s). This parameter must be derived
from the contrast agent concentration (not signal intensity) curve.
Thus the time-varying T1 measurement change must be measured.
IAUGC may be more reliable in the presence of noise or large
intravascular tracer concentration than other quantitative para-
meters, but as for pharmacokinetic modelling parameters, it
requires measurement of quantitative T1 changes. The relationship
between IAUGC and underlying physiology is complex and
undefined (Larcombe-McDouall et al, 1991; He and Evelhoch,
1998). Both IAUGC and Ktrans can be used to derive a ‘vascularised
tumour volume’ by counting the voxels with values above a
predetermined threshold.
It is recommended that the vascular Gd concentration –time
curve (ideally, the tumour arterial input function) should be
determined for each patient. The method and site of vascular
measurement should be appropriate to the tumour under
investigation. This is an area of current research, and may involve
direct arterial measurements, or generation of a normalisation
factor. Where this is not possible, steps should be taken to control
for differences in the input function either due to differences in
bolus injection, where use of a power injector is advised, or due
to changes in cardiovascular or renal function. The patient’s
cardiovascular function should be monitored and recorded, and
consideration should be given to measuring stroke volume, heart
rate and/or Gd uptake in normal tissue. These parameters can be
used to provide some normalisation for changes in arterial input to
a tumour.
IAUGC or Ktrans measurements should be made for each voxel in
the ROI or VOI. Ideally, 3D assessment of the entire tumour should
be made, since single-slice 2D assessments are (at least in theory)
prone to bias. Tumour volume should be assessed.
Secondary end points from DCE-MRI
Simplified methods of characterising DCE-MRI data, such as slope,
or time to maximum, have been reported and may be employed as
secondary end points. However, there is insufficient information
Box 6 Recommendations for MR measurement methods and end points
for use in phase 1/2a trials of anticancer therapeutics
Type of measurement
K Pharmacodynamic assessment should use T1-weighted studies of low-
molecular-weight Gd chelates.
K T2*-weighted studies may provide further information.
K Non-contrast-enhanced MRI may provide additional information.
K High-molecular-weight contrast agents may prove sensitive but are not
yet recommended.
Primary end points (terminology defined in Box 5)
K The primary end point should be either Ktrans (min1)) or IAUGC (mM
Gd min).
K Vascularised tumour volume can be obtained by summing voxels with
values above a predetermined threshold.
K Ideally, measurements of Ktrans or IAUGC should be made for each voxel
in the ROI or VOI.
K In tissues with substantial motion, ROI or VOI average measurements
may be more appropriate.
K Three-dimensional measurements are preferred, as single-slice
measurements (in theory) may be prone to bias due to incomplete
sampling and errors in positioning the slice.
K Tumour volume should be measured.
K All data including ROI definition and analysis should be recorded and
traceable to support external review.
Measurement requirements to assess Ktrans and IAUGC
Both Ktrans and IAUGC require calculation of instantaneous tumour Gd
concentration, based on the change in relaxation rate due to contrast uptake
DR1. This requires:
K An estimate of contrast agent relaxivity in tumour vasculature and tissue.
K Measurement of tumour T1 immediately prior to contrast uptake.
K An accurate T1 measurement method verified for all spatial locations,
coils and scanners used.
K Cardiac output (or arterial input function).
K Reproducible injection (ideally power injector).
Secondary end points
K Simplified methods of characterising the contrast time curve in DCE-MRI
are not recommended. They may be less sensitive than Ktrans or IAUGC
and are harder to compare between centres.
K Semiquantitative techniques are limited as they:
K May not accurately reflect tissue contrast agent concentration.
K May be influenced by contrast injection procedure, scanner settings,
adjustment and coil behaviour.
K May be influenced by cardiac output.
K Have a poorly defined relation to physiology.
K Comparison between patients and between systems is difficult.
K Other end points derived from compartmental models and DCE-MRI
such as vb, ve and kep may be of value.
K More elaborate pharmacokinetic models may improve evaluation of
dynamic data but are not yet supported by sufficient evidence to warrant
use as primary end points.
K Non-DCE-MRI secondary end points include T1, T2, T2*, diffusion,
perfusion from arterial spin tagging.
Trial design
K Entry criteria should consider tumour size in relation to pharmacological
mechanisms, MRI resolution and potential confounding from rapid
tumour growth rates.
K Investigators might consider dose escalation in individual patients,
allowing each subject to act as their own control.
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on the statistical power of these simplified approaches, and a priori
the reliance on a small portion of the DCE-MRI curve may make
them less sensitive than the use of Ktrans or IAUC. Also they may be
difficult to compare between centres. Other secondary end points
from compartmental models may also be employed. The use of
more elaborate models to derive secondary end points is
encouraged, although regard should be paid to the possibility that
complex models may not yield mathematically unique solutions.
vb: Methods are available to estimate vb although more
evaluation is required. Blood volume can be estimated from
dynamic T2*-weighted imaging (Sorensen et al, 1997), although
this usually precludes the simultaneous estimation of IAUGC or
Ktrans. Alternatively, simultaneous T1 and T2* data collection
techniques can be used (Barbier et al, 1999; Zhu et al, 2000; d’Arcy
et al, 2002). Recently, T1 measurements combined with modelling
methods have been developed for estimating brain blood volume
and permeability based on first-pass kinetics (Hacklander et al,
1996, 1997; Ludemann et al, 2001; Johnson et al, 2004). Roberts
et al (2000) have described a slow time resolution technique
for estimating blood volume and permeability in the brain. Such
T1-weighted techniques have a variable correlation with conven-
tional T2*-weighted techniques when estimating blood volume
(Hacklander et al, 1997; Zhu et al, 2000).
ve, extracellular extravascular volume, may be employed as a
secondary end point, although there is insufficient evidence that
ve provides an unbiased estimate of interstitial space, particularly
with noisy data in poorly perfused regions. Also, effective agents
might plausibly act either to increase or to decrease interstitial
volume fraction, making this an unreliable parameter for decision-
making.
kep: Similar considerations apply to kep (previously k21), which
reflects transfer of contrast from the extracellular space to the
plasma. It can be measured using low time resolution measure-
ments, and can also be derived from Ktrans/ve. Initial methods were
based on an assumption that signal intensity was proportional to
contrast agent concentration.
PS and vp: Endothelial permeability (PS) and the fractional
plasma volume (vp) can be derived from the use of macromole-
cular contrast agent (MMCM)-enhanced DCE-MRI (without the
flow contamination that can occur for Ktrans measured with current
low-molecular-weight ECF chelates (MWo1 kDa)). vp can also be
obtained from vb with a knowledge of haematocrit. The advantages
of using MMCMs include physiological relevance. Disadvantages
include lack of evaluation in human subjects, current nonavail-
ability for human use, signal-to-noise issues and the longer
scanning time required to estimate PS by monitoring the loss of
tracer from tumour.
Secondary end points from non-contrast-enhanced MRI
Tumour T1, T2, T2* relaxation times and the apparent diffusion
coefficient (Wheeler-Kingshott et al, 2003) may provide useful
measures of change. Perfusion using arterial spin tagging is of
interest as a secondary end point, although it has limited signal to
noise, and quantification is particularly demanding (Parkes and
Detre, 2003). Magnetisation transfer is sensitive to water molecules
bound to macromolecules and to cell membranes, and may
provide additional information about tissue changes (Tofts et al,
2003b).
Pharmacokinetic models
Three major models have been reported for leakage studies
(Larsson et al, 1990; Brix et al, 1991; Tofts et al, 1995). They are
reconciled by Tofts (1997). These models have been widely used,
and allow well-understood comparisons between studies to be
made. However, as with most models, they make a number of
assumptions. Generally, an assumed plasma washout curve is used,
based on the published Weinmann curve (Weinmann et al, 1984),
reflecting the change in plasma concentration with time due to
exchange and renal excretion. The Wienmann curve does not
provide information on the short-term vascular bolus and the
effects of bolus administration and vascular output on this. It
assumes normal renal function. Use of a measured arterial input
function can provide information on the short-term bolus
delivered to the tissue, the effects of cardiac output and longer
term exchange processes described by the plasma washout curve.
Experimental methods to measure this and incorporate it into
models are not yet common practice but are now being explored.
This in principle should allow for changes in physiology and bolus
administration, leading to increased reproducibility. The models
do not allow for intravascular tracer, which can be a major
component in tumours. The Brix model (Brix et al, 1991) assumes
that vascular leakage is permeability limited and that signal is
proportional to concentration. It also determines plasma decay
from the fit. Information on blood volume vb and perfusion can be
obtained from T2*–weighted bolus tracking measurements.
Models should calculate estimates of uncertainty by monitoring
fitting and w2; if the fit is poor for a given pixel or ROI, this should
be labelled as a model failure and excluded from further analysis
(e.g. ROI mean or histogram). The stability of fits with many
parameters should also be considered.
Analysis of regions of interest (ROI and VOI) (Box 7)
Most dynamic MRI studies utilise user-defined ROIs from image
slices or VOIs from 3D data sets. The ROI and VOI methods yield
graphical outputs with good signal-to-noise ratio, but lack spatial
resolution and are prone to partial volume averaging errors. In its
simplest form, an ROI or VOI encompassing the whole tumour
cross-sectional area or volume is drawn, from which an average
enhancement curve is extracted. Whole ROI analysis ignores
heterogeneity of tumour enhancement by assuming that the
averaged kinetic parameter estimate equates to those that would
be obtained from individual pixels. Recently, Hayes et al (2002)
have shown in primary breast cancer that whole ROI analysis can
be a close approximation to individual pixel evaluation. However,
many authors have commented that whole tumour VOI assessment
may be inappropriate, particularly for the evaluation of malignant
lesions where heterogeneous areas of enhancement are diagnos-
tically important (Aronen et al, 1994; Gribbestad et al, 1994; Parker
et al, 1997). Therefore, for some purposes, selective sampling of
regions within a tumour is used based on the premise that the
discrimination of lesions is improved by this approach (Liney et al,
1999). For evaluation of therapeutic response, selective sampling
may not be appropriate, unless good a priori criteria for region
selection can be developed.
Another approach for displaying dynamic data is by pixel
mapping (Parker et al, 1997). This method depicts kinetic
enhancement information as maps spatially coregistered with
anatomical images on a pixel-by-pixel basis. This type of display
has a number of advantages including the appreciation of
heterogeneity of enhancement and avoidance of the need to
selectively place user-defined ROIs. The risk of missing important
diagnostic information and of creating ROIs or VOIs that contain
more than one tissue type is reduced. An important advantage is
the ability to spatially match tumour vascular characteristics such
as blood volume, perfusion, transfer constant and leakage space.
Regional differences in the distributions of kinetic parameters have
been shown in xenografts (Bhujwalla et al, 2001) and human
tumours (Roberts et al, 2000; Zhu et al, 2000; Ludemann et al,
2001). Such displays provide unique insights into tumour
structure, function and response. As they avoid potential selection
bias in determining local ROIs or VOIs, they may have advantages
for monitoring treatment response to new agents. They may also
aid guidance of biopsy sampling of tumours.
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Pixel mapping techniques have the disadvantage of lower signal-
to-noise ratios, and they also require specialist software for their
generation (Hoffmann et al, 1995; Parker et al, 1998; Li et al, 2000).
While visual appreciation of heterogeneity is improved by pixel
mapping displays, quantification can be difficult. Recently,
histogram analysis (Tofts et al, 2003a) has been used to quantify
the heterogeneity of tumours for comparative and longitudinal
studies, for monitoring the effects of treatment and to show the
regression or development of angiogenic hot spots (Mayr et al,
2000; Hayes et al, 2002). Recommendations regarding the analysis
of ROI or VOI are summarised in Box 7.
STANDARDISATION, VALIDATION AND
REPRODUCIBILITY (Box 8)
To support the use of MR parameters in decision-making with
regard to pharmaceuticals, it is important to show correlations
between specific biological effects, their magnitude and the
relevant MR parameter. This should be firstly performed in well-
defined model systems, and then, where possible, confirmed by
clinical measurements using tumour biopsy or if appropriate,
surrogate tissues, taking into account the expected time course of
activity. The biological end points ideally should relate specifically
to the proposed mechanism of action of the compound. To allow
appropriate study design, and to assess the significance of change,
centres should demonstrate the reproducibility of their clinical
measurements, in a manner that is traceable, providing informa-
tion on individual and intergroup reproducibility. This informa-
tion should be combined with evidence of the expected magnitude
of therapeutic effect, such that the design can enable assessment
of dose-related changes. Such assessment can be facilitated by
incorporating baseline repeat measurements to provide informa-
tion directly relevant to the body sites chosen.
It is recommended that standardised methods of analysis, as
discussed in the previous section, be used. In order to allow
comparison of different centres’ analysis methods, and to enable
assessment of new models, there is a need for standardised data
sets to be made available. These should be documented,
anonymised and be widely accessible (for example, via the world
wide web). It would be advantageous if companies and academic
investigators conducting trials could make data available in this
form. Similarly, it would be desirable for research groups to make
their analysis methods available either by publication of open
code, or under specific sharing agreements. This policy would
benefit the whole user community. In the longer term, specific
standardised software for analysis would be advantageous, but this
should not restrict the continual evolution of measurement and
analysis approaches. Standard methods of T1 assessment should
be established and validated against phantoms appropriate to
specific body locations, with their measurement reproducibility
being established. It is thought that there is limited value in direct
comparison of different methods, which is only supported where
there is likely to be a clear improvement. In these cases,
comparison of IAUGC and/or Ktrans is required as a minimum.
Where multiple sites are participating in a trial, the methodology
should be standardised and confirmed using imaging phantoms
and a quality assurance programme. Data analysis should ideally
be performed centrally, using validated software. Reliability of this
analysis should be assured using data from each participating
centre prior to starting the trial. Recommendations for standardi-
sation, validation and reproducibility are summarised in Box 8.
Box 7 Recommendations for analysis of DCE-MRI data in ROI or VOI
K Before placement of an ROI or VOI, individual images should be examined
for the presence of patient motion, best seen on subtraction images.
K Ideally, dynamic image data sets should be spatially registered before
analysis.
K Both early (60–120 s after contrast) and late (more than 5 min after
contrast) subtraction images should be generated.
K Ideally, the early subtraction images will determine the position for ROI or
VOI placement.
K If early enhancement is low, the late subtraction data set should be used.
K If no enhancement is seen, the baseline data (nonenhanced) aided by
conventional images should be used for ROI or VOI placement.
K The outer limit of the lesion should act as a boundary of the ROI or VOI
to minimise partial volume effects.
K Areas of necrosis and adjacent blood vessels should be excluded.
K The ROI or VOI should be constant in position and size for each image in
the series under analysis.
K The position of the ROIs or VOIs, corresponding graphs and tables of
enhancement values should be recorded, ideally in digital and hard copy
form for future reference.
K In the event of significant motion, it may be necessary to adjust the ROI or
VOI position on each image, measuring only a mean value.
K Analysis should take account of potential partial volume and ROI or VOI
shape.
Box 8 Standardisation, validation and reproducibility
Validation of MRI in relation to end points of action
K Require correlation between size and type of biological effect and relevant
MR parameter, in animal models, supported by clinical biopsy data.
K Time course of effects of rapidly acting agents needs to be defined.
K Require hypothesis-driven relationships between imaging and specific
biological end points.
K Biological end points should relate to the mechanism of activity of the
compound.
K It would be desirable to be able to predict the magnitude of the MR effect
based on animal models, allowing trial design to monitor dose-related
change.
What validation/evidence of reproducibility is required ?
K Centres should define reproducibility of data that is traceable, for
individuals and intergroup comparisons, allowing the power of studies to
be defined prospectively for a defined end point.
K Where possible, and in the absence of existing reproducibility data specific
to the method, two baseline measurements should be incorporated to
allow assessment of individual patient reproducibility.
K A standardised minimum statistical approach for reproducibility analysis
should be defined.
Standardisation of measurement methods
K Basic standards for measurements of T1 should be established and
adhered to. They should be tested against relevant phantoms, and
reproducibility established.
K New techniques need to demonstrate specific advantages over existing
methods, providing comparison data that define the benefit.
K In multicentre trials using identical (preferred), similar or different
methods, comparison of precision and accuracy should be determined on
phantoms, to provide a basis for pooling data, with account taken of
correction for machine-specific factors, and for sensitivity to motion effects
not seen in phantoms.
K Studies should include routine measurement and analysis quality
assurance.
Validation of analysis methods
K Standardised data sets need to be made available to allow testing and
comparison of analysis approaches.
K Research groups should make analysis methods available, either as open
source code or by specific agreements where there are confidential or
commercial issues.
K Standardisation of software for analysis would be desirable.
K Centres should be able to demonstrate that software is ‘fit for purpose’.
K Analysis of dynamic contrast-enhanced data in any multicentre trial should
be performed at a single centre using validated software.
K Performance of measurements at each site should be validated at analysis
site, prior to recruitment using standardised data from each site.
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FUTURE DEVELOPMENTS (Box 9)
MRI methods for use with antivascular and antiangiogenic drugs
are still in their infancy, and rapid progress is likely in the next few
years. There is an urgent need for further developments to
facilitate the use of DCE-MRI. An underlying requirement is the
need for a rapid and robust method for measuring T1, to allow
contrast agent concentration to be estimated from measured signal
intensity (Parker et al, 2001; Gowland and Stevenson, 2003). Rapid
T1 measurement methods should be implemented by instrument
manufacturers, together with standard protocols for calibrating
and testing them. Correction for variation in the plasma
concentration of contrast agent has been shown to be an important
source of variation between measurements, limiting reproduci-
bility. Measurement of arterial input function or generation of a
normalising function based on nearby normal tissues are methods
that are under development. The value of these approaches needs
to be defined, and a standardised method developed and
incorporated into analysis techniques. Improved statistical analy-
sis techniques suitable for interrogating the parameter values
within an ROI, which may define the whole tumour, are required.
Current techniques employing simple descriptors of the histogram
of parameter values, although more sensitive than simple ROI
analysis, may not be optimised to detect the changes caused by a
new agent in a phase I trial. Recommendations for future
development are listed in Box 9.
In the longer term, there is a need for improved contrast agents,
either with higher molecular weight or with functionally specific
properties, to provide a read-out of direct therapeutic action.
Measurements at many sites in the body are compromised by
tissue motion, or by the physiological effects of nearby tissue
motion. While sophisticated methods have been applied to, for
example, cardiac imaging, these are generally not immediately
applicable to other organs or tissues. Motion compensating or
correcting techniques, which preserve the timing and quantitative
nature of contrast measurements, are required, together with
appropriate registration techniques. A range of other physiological
and metabolic parameters can be measured that may inform the
action of new therapeutics, and may aid discrimination of different
tissue types within tumour. There is likely to be value in applying
these additional approaches to tumour measurements, and
developing appropriate combined analyses.
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site standardisation of measurements and evaluation.
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